EVUSHELD

This brand name is authorized in Austria, Australia, Canada, Estonia, Ireland, Japan, Lithuania, Poland, Romania, United States

Active ingredients

The drug EVUSHELD contains a combination of these active pharmaceutical ingredients (APIs):

1 Tixagevimab UNII F0LZ415Z3B - TIXAGEVIMAB

2 Cilgavimab UNII 1KUR4BN70F - CILGAVIMAB

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
EVUSHELD Solution for injection	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
J06BD03		J Antiinfectives for systemic use → J06 Immune sera and immunoglobulins → J06B Immunoglobulins → J06BD Antiviral monoclonal antibodies
Discover more medicines within J06BD03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: CA	Health Products and Food Branch	Identifier(s): 02526271
Country: EE	Ravimiamet	Identifier(s): 1879926
Country: JP	医薬品医療機器総合機構	Identifier(s): 62505A1A1028
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1094411
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100466622
Country: RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	Identifier(s): W68715001
Country: US	FDA, National Drug Code	Identifier(s): 0310-1061, 0310-7442, 0310-8895